FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC: Form 990, tax year 2023

View the entire original 990 at ProPublica ↗

Organization: FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC (EIN 52-1986675)
Tax period: 2023-01-01 to 2023-12-31
Filed: 2024-11-13
IRS object ID: 202443189349301314
Schema version: 2023v5.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2024-11-13T06:28:03+00:00	ReturnTs
Tax Period End	2023-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	440160260	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	Forvis Mazars LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	901 East Cary Street Suite 1000	AddressLine1Txt
City	Richmond	CityNm
State Abbreviation	VA	StateAbbreviationCd
ZIP	23219	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2023-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	521986675	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	Foundation for the National Institutes of Health Inc	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	FOUN	BusinessNameControlTxt
Phone	3014025311	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	11400 Rockville Pike 600	AddressLine1Txt
City	North Bethesda	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20852	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	Donald M Hill	PersonNm
Person Title	Chief Financial Officer	PersonTitleTxt
Signature	2024-11-13	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	Yes (true)	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	LaKrisha Castleberry	PreparerPersonNm
PTIN	P01677333	PTIN
Phone	8042827636	PhoneNum
Preparation	2024-11-13	PreparationDt

Field	Value	IRS element (for citing)
Tax	2023	TaxYr
Build TS	2024-10-15 13:58:12Z	BuildTS

Form 990 IRS990

Principal Ofcr Business Name PrincipalOfcrBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	Donald M Hill	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	11400 Rockville Pike 600	AddressLine1Txt
City	North Bethesda	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20852	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$302,514,473	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	http://www.fnih.org	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1996	FormationYr
Legal Domicile State	MD	LegalDomicileStateCd
Activity Or Mission	The Foundation for the National Institutes of Health (FNIH) builds public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health and equity in care; and celebrates and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visitfnih.org.	ActivityOrMissionDesc
Voting Members Governing Body	21	VotingMembersGoverningBodyCnt
Voting Members Independent	20	VotingMembersIndependentCnt
Total Employee	107	TotalEmployeeCnt
Total Volunteers	20	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$68,998,263	PYContributionsGrantsAmt
CY Contributions Grants	$56,092,197	CYContributionsGrantsAmt
PY Program Service Revenue	$50,000	PYProgramServiceRevenueAmt
CY Program Service Revenue	$50,000	CYProgramServiceRevenueAmt
PY Investment Income	$1,459,757	PYInvestmentIncomeAmt
CY Investment Income	$4,762,392	CYInvestmentIncomeAmt
PY Other Revenue	$77,179	PYOtherRevenueAmt
CY Other Revenue	$61,199	CYOtherRevenueAmt
PY Total Revenue	$70,585,199	PYTotalRevenueAmt
CY Total Revenue	$60,965,788	CYTotalRevenueAmt
PY Grants And Similar Paid	$32,121,575	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$20,270,897	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$12,734,826	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$16,465,315	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$218,308	CYTotalFundraisingExpenseAmt
PY Other Expenses	$32,561,709	PYOtherExpensesAmt
CY Other Expenses	$32,908,531	CYOtherExpensesAmt
PY Total Expenses	$77,418,110	PYTotalExpensesAmt
CY Total Expenses	$69,644,743	CYTotalExpensesAmt
PY Revenues Less Expenses	-$6,832,911	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$8,678,955	CYRevenuesLessExpensesAmt
Total Assets BOY	$216,582,542	TotalAssetsBOYAmt
Total Assets EOY	$206,113,368	TotalAssetsEOYAmt
Total Liabilities BOY	$18,255,107	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$12,576,790	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$198,327,435	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$193,536,578	NetAssetsOrFundBalancesEOYAmt
Mission	See Schedule O, Statement of Organization's Primary Exempt Purpose Statement To create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$58,235,139	ExpenseAmt
Grant	$19,658,554	GrantAmt
Revenue	$50,000	RevenueAmt
Desc	SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMS New Public-Private Partnership Supports Development of Pediatric Medical Devices Despite efforts to support innovation in pediatric medical devices, challenges remain in developing these technologies for children, including concerns about device longevity and long-term exposure to implanted materials. The FNIH announced the launch of a project design phase to address the gap in availability of these devices. The project is supported by a public-private partnership between the NIH, the U.S. Food and Drug Administration, the Biomedical Advanced Research and Development Authority, and partners from the private sector. A full-scale pediatric medical device public-private partnership project will follow the design phase, with the goal of developing a sustainable infrastructure for creating and commercializing these devices. STRENGTHENING THE PATIENT VOICE The FNIH puts patients first. When their perspectives are incorporated into our work, the result will be faster medical breakthroughs for some of today's most pressing health challenges. To do this, we work closely with our Patient Ambassadors, made up of people with lived experience of a disease, and our Patient Engagement Council, comprised of representatives of patient-centric organizations. The Council convened its first Patient Summit in 2023. Six Patient Ambassadors, ten members of the Council, and FNIH staff members who attended the day-long event identified and discussed strategies to better involve and engage people with health challenges in FNIH projects. RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH Award-Winning A-PLUS Study: Improving Outcomes for Laboring Women Worldwide Maternal sepsis affects an estimated 6 million women per year and is the third most commoncause of maternal mortality globally. The Azithromycin Prevention in Labor Use Study (A-PLUS), a groundbreaking multinational clinical trial, demonstrated that one dose of azithromycin, a low-cost, generic, oral antibiotic, given during labor to women planning to deliver vaginally could reduce the occurrence of life-threatening sepsis. Initial study results, published in the New England Journal of Medicine and presented at the Society for Maternal-Fetal Medicine's Pregnancy Meeting 2023, showed that azithromycin use cut the risk of maternal sepsis by 35% and could prevent up to 2 million such cases per year. Global Pandemic Treaty: FNIH Convenes, Informs Leaders The member countries of the World Health Organization (WHO) continued negotiation of a pandemic agreement to "address gaps in preventing, preparing for, and responding to health emergencies [through] a comprehensive and coherent approach to strengthen the global health architecture ... with a whole-of-government and whole-of-society approach, prioritizing the need for equity." The FNIH in 2023 continued its work to inform WHO and the global community as it considers the treaty. The FNIH, in partnership with WHO's collaborating center at Georgetown University's O'Neill Institute for National and Global Health Law, convened two high-level global consultations to provide technical advice and information on key topics identified by the WHO's Intergovernmental Negotiating Body (INB) as critical for the treaty's success. - In collaboration with UNAIDS, convened an expert group to consider existing models that assert equity as a priority and analyze them for possible inclusion in the treaty. Attendees included: INB Co-Chair Precious Matsoso and senior WHO observers assisting the INB. Report of the convening: Advancing a World Together Equitably - In collaboration with the University of Cape Town, organized a global meeting on the development and deployment of emergency countermeasures, including vaccines, diagnostics, and treatments. The expert group examined case studies for countermeasure development, pandemic clinical trial capabilities, and access and benefit sharing. Report of the convening: Emergency Countermeasure Development and Deployment Thought pieces providing insights into pandemic preparedness were published in Hastings Center Reports and Health Affairs Forefront.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$1,369,576	ExpenseAmt
Grant	$612,343	GrantAmt
Desc	SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS PROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - POWERING SCIENCE: 2023 FNIH AWARDS The Lurie Prize in Biomedical Sciences The 2023 Lurie Prize in Biomedical Sciences recognized the outstanding achievements of two researchers, each of whom has made important and distinct discoveries in the field of mitochondrial science. Both awardees achieved milestones in biomedical science by exploring the characteristics and functions of mitochondria in human physiology and disease. The award included a $100,000 honorarium, split between the two awardees and made possible by a donation to the FNIH by philanthropist Ann Lurie, President of the Ann and Robert H. Lurie Foundation, President of Lurie Holdings, Inc., and Honorary FNIH Board Member. A distinguished jury of biomedical researchers, chaired by FNIH board member Solomon H. Snyder, MD, selected the 2023 winners. 2023 Award Recipient: Navdeep S. Chandel, PhD, is the David W. Cugell Professor of Medicine, Biochemistry, and Molecular Genetics at Northwestern University Feinberg School of Medicine. The Chandel research team has shown that mitochondria do much more than supply energy to cells. His research team has revealed how mitochondria function as signaling organelles that control the body's normal functions and impact diseases, including cancer and inflammation. 2023 Award Recipient: Vamsi Mootha, MD, is an investigator of the Howard Hughes Medical Institute, investigator in the Department of Molecular Biology at Massachusetts General Hospital, a member of the Broad Institute of MIT and Harvard, and a professor of Systems Biology and Medicine at Harvard Medical School. Although mitochondria contain their own DNA that encodes just 13 proteins, the Mootha research team has identified the other 99% of mitochondrial proteins encoded by nuclear DNA and compiled their findings in a widely used reference tool used to discover new protein functions and disease genes. Trailblazer Prize for Clinician-Scientists The FNIH Trailblazer Prize for Clinician-Scientists recognizes the outstanding contributions of early career clinician-scientists whose work has the potential to, or has led to, innovations in patient care. In searching for potential winners, we seek to highlight true scientific innovators - and this year was no exception. The award celebrates the transformational work of individuals whose research translates basic scientific observations into new paradigm-shifting approaches for diagnosing, preventing, treating, or curing disease and disability. The Trailblazer Prize is made possible by a generous donation from John I. Gallin, MD, and Elaine Gallin, PhD, to the FNIH. 2023 Award Recipient: Vinod Balachandran, MD, is a physician-scientist in the Immuno-Oncology Service of the Human Oncology and Pathogenesis Program and a surgical oncologist at Memorial Sloan Kettering Cancer Center, where he is also immunology group leader in the David M. Rubenstein Center for Pancreatic Cancer Research. Dr. Balachandran discovered that rare long-term survivors of pancreatic cancer have unique tumors enriched in neoantigens - foreign proteins arising from cancer mutations - which may trigger immune cells to keep pancreatic cancers in check. He is now translating these laboratory discoveries into new immunotherapies for pancreatic cancer, including the first clinical trials of personalized mRNA vaccines that target neoantigens to provoke the patient's immune system to recognize their individual cancer. Charles A. Sanders, MD, Partnership Award In honor of former FNIH Chairman of the Board Charles A. Sanders, MD, we celebrate our partners and their contributions through the annual Partnership Award. In keeping with Dr. Sanders' vision, the award recognizes persons and/or organizations that have made significant contributions to our work in creating, implementing, and nurturing public-private partnerships that build bridges to breakthroughs in improved therapeutics, diagnostics, and potential cures. A committee comprised of FNIH Board members selected three partners for 2023 who have supported and accelerated the work of the FNIH for many years. 2023 Award Recipient: The National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The NICHD and the FNIH worked together to manage programs initiated by NICHD's Global Network for Women's and Children's Health Research with additional support from the Bill & Melinda Gates Foundation. These collaborations centered on two clinical trials in critical areas of maternal health: The Azithromycin Prevention in Labor Use Study (A-PLUS) and the Prevention of Iron Deficiency Anemia Post-Delivery (PRIORITY) trial. 2023 Award Recipient: GSK. GSK has been a major FNIH partner, supporting more than 35 projects. As longstanding partners of the Biomarkers Consortium, GSK has helped accelerate and advance discovery, development, and regulatory approval for biomarkers that support new drug therapeutics, preventive medicine, and diagnostics. GSK also has supported AMP Programs, tuberculosis research, and families staying at the Edmond J. Safra Family Lodge, which helps guests remain near loved ones being treated at the NIH Clinical Center. 2023 Award Recipient: The O'Neill Family. For 20 years, the O'Neill family has partnered with the FNIH to raise visibility and funds for kidney cancer research. The Dean R. O'Neill Renal Cell Cancer Research Fund supports research fellowships in the laboratory of Dr. Richard Childs at the NIH's National Heart, Lung, and Blood Institute to search for a cure for renal cell carcinoma. To date, fellowships have supported the work of ten distinguished scientists. EVENTS AND EDUCATION The Meetings and Events Department conceptualizes, plans, executes and evaluates high-quality, productive, innovative and economical convenings that advance the organization's mission. These convenings include, but are not limited to, research project team meetings and conferences, donor stewardship lectures and symposia, and special events. The department oversees the management of the FNIH's highly respected awards and prizes. In collaboration with the NIH and our generous donors and partners, we manage training initiatives that offer educational opportunities to science students, ranging from high school to post-doctoral scholars, crossing boundaries and cultures. They learn through intensive training, collaborative engagement, mentoring, and hands-on research. Legacy funds from individual benefactors and foundations help move scientific achievement farther, faster, and give hope to future patients. Individual programs provide financial support, mentoring, and recognition to promising young scientists. Here is a just a sample of how the FNIH powers science: - The Medical Research Scholars Program is a one-year intensive training program on the NIH campus offering medical, dental and veterinary students opportunities to become engaged in research early in their careers. The goal is to train the best and brightest students today to produce the leading clinicians and researchers of tomorrow. The FNIH has supported a total of 572 scholars since the program was established. - The Deeda Blair Research Initiative for Disorders of the Brain announced in 2023 its second round of awards to drive innovation in mental health research. Four awardees each received $100,000. - We support scientists and promote them through annual lectures at the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the National Institute of Allergy and Infectious Diseases, the National Center for Complementary and Integrative Health, and elsewhere. - For a complete list of all the ways the FNIH is powering science, go to the FNIH website.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$59,604,715	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Donor Advised Fund	Yes (true)	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (true)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	Yes (true)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (true)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	false	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	false	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	Yes (true)	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	false	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	58	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	107	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	false	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
DAF Excess Business Holdings	false	DAFExcessBusinessHoldingsInd
Taxable Distributions	false	TaxableDistributionsInd
Distribution To Donor	false	DistributionToDonorInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	21	GoverningBodyVotingMembersCnt
Independent Voting Member	20	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	Yes (true)	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	false	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	DONALD M HILL	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	3014356246	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	11400 ROCKVILLE PIKE 600	AddressLine1Txt
City	NORTH BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20852	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (33 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
Dr Julie L Gerberding
Chief Executive Officer	40.0	Yes (X)	Yes (X)	$613,755	$0	$43,274
Charles A Reinhart III
Board Member	0.5	Yes (X)		$0	$0	$0
Dame Jillian Sackler
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Charles A Sanders
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Edison T Liu
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Elias Zerhouni
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Ellen V Sigal
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Freda Lewis-Hall
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Judy Lansing Kovler
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Paul Stoffels
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Ronald L Krall
Board Member	0.5	Yes (X)		$0	$0	$0
Dr Solomon H Snyder
Vice-Chairman	0.5	Yes (X)		$0	$0	$0
Dr Steven M Paul
Chairman	1.5	Yes (X)		$0	$0	$0
Gilbert S Omenn
Board Member	0.5	Yes (X)		$0	$0	$0
James Weiss
Board Member	0.5	Yes (X)		$0	$0	$0
Jay Bradner
Board Member	0.5	Yes (X)		$0	$0	$0
Mr Fred Seigel
Board Member	0.5	Yes (X)		$0	$0	$0
Mr James H Donovan
Board Member	0.5	Yes (X)		$0	$0	$0
Mr Russell W Steenberg
Board Member	0.5	Yes (X)		$0	$0	$0
Mrs William McCormick Blair Jr
Secretary	1.0	Yes (X)		$0	$0	$0
Ms Julie Bell Lindsay
Treasurer	2.0	Yes (X)		$0	$0	$0
David Carmel
Senior Vice President, Chief Growth and Innovation Officer	40.0			$400,911	$0	$40,224	Yes (X)
David Wholley
Chief Strategy and Business Development (UNTIL NOV.)	40.0			$375,609	$0	$39,802	Yes (X)
Donald Hill
Senior Vice President, Chief Financial Officer	40.0			$289,166	$0	$40,393	Yes (X)
Joseph Menetski
Senior Vice President, Chief Translational Science Officer	40.0			$324,692	$0	$39,943	Yes (X)
Julie Wolf Rodda
Chief Strategic Alliances and Advancement Officer (UNTIL NOV.)	40.0			$180,943	$0	$17,503	Yes (X)
Kevin Klock
Senior Vice President, Chief Operating Officer and General Counsel	40.0			$283,492	$0	$37,823	Yes (X)
Michael Santos
Senior Vice President, Chief Population Health Science Officer	40.0			$368,742	$0	$34,416	Yes (X)
Courtney Silverthorn
Associate Vice President, Science Partnerships Translational Science	40.0			$236,430	$0	$27,203		Yes (X)
Eva Coyne
Vice President -Controller	40.0			$231,174	$0	$32,796		Yes (X)
Robert Balthaser
Vice President of Advancement (UNTIL NOV.)	40.0			$220,316	$0	$20,295		Yes (X)
Stacey Adam
Associate Vice President, Science Partnerships Translational Science	40.0			$258,208	$0	$28,555		Yes (X)
Steven Hoffmann
Associate Vice President, Science Partnerships Translational Science	40.0			$240,048	$0	$33,223		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$4,023,486	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$435,450	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	59	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	Address Line2ContractorAddress/USAddress/AddressLine2Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
SWOG CTI
24 FRANK LLOYD WRIGHT DRIVE	PO Box 483	ANN ARBOR	MI	48105	clinical trial for Lung Map Project	$3,519,264
The Trustees of Columbia University
154 Haven Avenue 2nd Floor		New York	NY	10032	AMP AD 2.0 Project Research Collaboration	$2,050,540
Emory University
1599 Clifton Road NE 4th floor		Atlanta	GA	30322	AMP AD 2.0 Project Research Collaboration	$1,923,678
Dana -Farber Cancer Institute
451 Brookline Avenue		Boston	MA	02216	The PACT, MRD and ctDNA Research Collaboration	$1,808,688
Deloitte Consulting LLP
4022 Sells Drive		Hermitage	TN	37076	covid-19 project PROFESSIONAL SERVICES	$1,699,092

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	40	CntrctRcvdGreaterThan100KCnt
Fundraising	$333,929	FundraisingAmt
Government Grants	$1,250,000	GovernmentGrantsAmt
All Other Contributions	$54,508,268	AllOtherContributionsAmt
Noncash Contributions	$6,019,419	NoncashContributionsAmt
Total Contributions	$56,092,197	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	Administrative Revenue	Desc
Business	900099	BusinessCd
Total Revenue Column	$50,000	TotalRevenueColumnAmt
Related Or Exempt Func Income	$50,000	RelatedOrExemptFuncIncomeAmt

Total Oth Program Service Rev TotalOthProgramServiceRevGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$50,000	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$4,421,167	TotalRevenueColumnAmt
Exclusion	$4,421,167	ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$241,379,578	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$241,038,353	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$341,225	SecuritiesAmt
Other	$0	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$341,225	TotalRevenueColumnAmt
Exclusion	$341,225	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$571,531	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$333,929	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$510,332	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$61,199	TotalRevenueColumnAmt
Exclusion	$61,199	ExclusionAmt

Miscellaneous Revenue MiscellaneousRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$0	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$60,965,788	TotalRevenueColumnAmt
Related Or Exempt Func Income	$50,000	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$4,823,591	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$19,846,427	TotalAmt
Program Services	$19,846,427	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$402,500	TotalAmt
Program Services	$402,500	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$21,970	TotalAmt
Program Services	$21,970	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$3,130,688	TotalAmt
Program Services	$844,776	ProgramServicesAmt
Management And General	$2,285,912	ManagementAndGeneralAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$9,734,008	TotalAmt
Program Services	$6,558,766	ProgramServicesAmt
Management And General	$3,138,422	ManagementAndGeneralAmt
Fundraising	$36,820	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$583,866	TotalAmt
Program Services	$330,553	ProgramServicesAmt
Management And General	$242,375	ManagementAndGeneralAmt
Fundraising	$10,938	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$2,107,570	TotalAmt
Program Services	$1,277,093	ProgramServicesAmt
Management And General	$785,497	ManagementAndGeneralAmt
Fundraising	$44,980	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$909,183	TotalAmt
Program Services	$442,389	ProgramServicesAmt
Management And General	$466,794	ManagementAndGeneralAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$402,168	TotalAmt
Program Services	$323,560	ProgramServicesAmt
Management And General	$72,647	ManagementAndGeneralAmt
Fundraising	$5,961	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$119,100	TotalAmt
Program Services	$17,325	ProgramServicesAmt
Management And General	$101,775	ManagementAndGeneralAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$202,355	TotalAmt
Management And General	$202,355	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$91,619	TotalAmt
Program Services	$87,280	ProgramServicesAmt
Management And General	$3,868	ManagementAndGeneralAmt
Fundraising	$471	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$53,990	TotalAmt
Program Services	$4,411	ProgramServicesAmt
Management And General	$49,579	ManagementAndGeneralAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$178,584	TotalAmt
Program Services	$57,476	ProgramServicesAmt
Management And General	$118,585	ManagementAndGeneralAmt
Fundraising	$2,523	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$735,836	TotalAmt
Program Services	$181,754	ProgramServicesAmt
Management And General	$554,082	ManagementAndGeneralAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$2,172,051	TotalAmt
Program Services	$1,860,586	ProgramServicesAmt
Management And General	$242,530	ManagementAndGeneralAmt
Fundraising	$68,935	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$214,733	TotalAmt
Management And General	$214,733	ManagementAndGeneralAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$241,927	TotalAmt
Program Services	$131,491	ProgramServicesAmt
Management And General	$110,436	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
Program Contracts	$22,630,837	$22,621,565	$9,272
Consultants	$5,085,754	$4,117,010	$925,735	$43,009
Bad Debt Expense	$868,750	$868,750
Recruiting	$246,367	$96,050	$150,317

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	-$335,540	TotalAmt
Program Services	-$487,017	ProgramServicesAmt
Management And General	$146,806	ManagementAndGeneralAmt
Fundraising	$4,671	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$69,644,743	TotalAmt
Program Services	$59,604,715	ProgramServicesAmt
Management And General	$9,821,720	ManagementAndGeneralAmt
Fundraising	$218,308	FundraisingAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$73,162,269	BOYAmt
EOY	$33,349,260	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$49,795,550	BOYAmt
EOY	$42,017,805	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$255,982	BOYAmt
EOY	$366,589	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$3,158,809	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$1,688,166	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$1,571,232	BOYAmt
EOY	$1,470,643	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$84,510,224	BOYAmt
EOY	$120,900,511	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$7,287,285	BOYAmt
EOY	$8,008,560	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$216,582,542	BOYAmt
EOY	$206,113,368	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$8,918,557	BOYAmt
EOY	$4,105,123	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$783,334	BOYAmt
EOY	$408,334	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$8,553,216	BOYAmt
EOY	$8,063,333	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$18,255,107	BOYAmt
EOY	$12,576,790	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$27,430,780	BOYAmt
EOY	$32,672,601	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$170,896,655	BOYAmt
EOY	$160,863,977	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$198,327,435	BOYAmt
EOY	$193,536,578	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$216,582,542	BOYAmt
EOY	$206,113,368	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$8,678,955	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$3,888,098	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Info In Schedule O Part XII	Yes (X)	InfoInScheduleOPartXIIInd
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	Yes (true)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (true)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$50,623,645	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$98,343,956	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$105,993,785	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$68,998,263	CurrentTaxYearMinus1YearAmt
Current Tax Year	$56,092,197	CurrentTaxYearAmt
Total	$380,051,846	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$50,623,645	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$98,343,956	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$105,993,785	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$68,998,263	CurrentTaxYearMinus1YearAmt
Current Tax Year	$56,092,197	CurrentTaxYearAmt
Total	$380,051,846	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$120,629,819	SubstantialContributorsTotAmt
Public Support Total170	$259,422,027	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$2,818,334	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,722,957	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,346,882	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$2,204,173	CurrentTaxYearMinus1YearAmt
Current Tax Year	$4,421,167	CurrentTaxYearAmt
Total	$12,513,513	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$0	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$0	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$0	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$0	CurrentTaxYearMinus1YearAmt
Current Tax Year	$0	CurrentTaxYearAmt
Total	$0	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$392,565,359	TotalSupportAmt
Gross Receipts Rltd Activities	$100,000	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.6608	PublicSupportCY170Pct
Public Support PY170	0.6353	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	false	VolunteersInd
Paid Staff Or Management	Yes (true)	PaidStaffOrManagementInd
Media Advertisements	false	MediaAdvertisementsInd
Mailings Members	false	MailingsMembersInd
Publications Or Broadcast	false	PublicationsOrBroadcastInd
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Direct Contact Legislators	Yes (true)	DirectContactLegislatorsInd
Direct Contact Legislators	$0	DirectContactLegislatorsAmt
Total Lobbying Expenditures	$0	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY	FormAndLineReferenceDesc
Explanation	FNIH consulted its Congressional committees of jurisdiction on public health legislation.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Donor Advised Funds Held	1	DonorAdvisedFundsHeldCnt
Funds And Other Accounts Held	0	FundsAndOtherAccountsHeldCnt
Donor Advised Funds Contri	$10,100	DonorAdvisedFundsContriAmt
Funds And Other Accounts Contri	$0	FundsAndOtherAccountsContriAmt
Donor Advised Funds Grants	$32,634	DonorAdvisedFundsGrantsAmt
Funds And Other Accounts Grants	$0	FundsAndOtherAccountsGrantsAmt
Donor Advised Funds Vl EOY	$209,076	DonorAdvisedFundsVlEOYAmt
Funds And Other Accounts Vl EOY	$0	FundsAndOtherAccountsVlEOYAmt
Disclosed Org Leg Ctrl	Yes (true)	DisclosedOrgLegCtrlInd
Disclosed For Charitable Prps	Yes (true)	DisclosedForCharitablePrpsInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$20,829,215	BeginningYearBalanceAmt
Contributions	$1,847,034	ContributionsAmt
Investment Earnings Or Losses	$523,194	InvestmentEarningsOrLossesAmt
Administrative Expenses	$259,144	AdministrativeExpensesAmt
End Year Balance	$22,940,299	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$24,511,134	BeginningYearBalanceAmt
Contributions	-$85,775	ContributionsAmt
Investment Earnings Or Losses	-$788,802	InvestmentEarningsOrLossesAmt
Administrative Expenses	$2,807,342	AdministrativeExpensesAmt
End Year Balance	$20,829,215	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$20,878,035	BeginningYearBalanceAmt
Contributions	$3,154,350	ContributionsAmt
Investment Earnings Or Losses	$544,664	InvestmentEarningsOrLossesAmt
Administrative Expenses	$65,915	AdministrativeExpensesAmt
End Year Balance	$24,511,134	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$14,897,505	BeginningYearBalanceAmt
Contributions	$5,648,998	ContributionsAmt
Investment Earnings Or Losses	$419,982	InvestmentEarningsOrLossesAmt
Administrative Expenses	$88,450	AdministrativeExpensesAmt
End Year Balance	$20,878,035	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$12,514,811	BeginningYearBalanceAmt
Contributions	$1,788,682	ContributionsAmt
Investment Earnings Or Losses	$705,900	InvestmentEarningsOrLossesAmt
Administrative Expenses	$111,888	AdministrativeExpensesAmt
End Year Balance	$14,897,505	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.7772	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.2228	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.0	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,869,159	OtherCostOrOtherBasisAmt
Depreciation	$720,537	DepreciationAmt
Book Value	$1,148,622	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,289,650	OtherCostOrOtherBasisAmt
Depreciation	$967,629	DepreciationAmt
Book Value	$322,021	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$1,470,643	TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
Charitable Gift Annuity	$108,473
Operating Lease Liability	$7,954,860

Field	Value	IRS element (for citing)
Total Liability	$8,063,333	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$65,529,899	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$3,888,098	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$368,036	DonatedServicesAndUseFcltsAmt
Other Revenue	$0	OtherRevenueAmt
Revenue Not Reported	$4,256,134	RevenueNotReportedAmt
Revenue Subtotal	$61,273,765	RevenueSubtotalAmt
Investment Expenses Not Incld	$202,355	InvestmentExpensesNotIncldAmt
Other Revenues Not Included	-$510,332	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	-$307,977	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$60,965,788	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$70,320,756	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$368,036	DonatedServicesUseFcltsAmt
Other Expenses Included	$510,332	OtherExpensesIncludedAmt
Expenses Not Reported	$878,368	ExpensesNotReportedAmt
Expenses Subtotal	$69,442,388	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$202,355	InvestmentExpensesNotIncld2Amt
Other Expenses Not Included	$0	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$202,355	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$69,644,743	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (4 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule D, Part V, Line 4 Intended uses of endowment funds	The Foundation has one endowment that is funded by multiple donors to seed new discoveries and/or be available to respond to epidemics and Foundation's unanticipated needs. The Foundation's other endowments consist of individual donor-restricted endowment funds established for a variety of purpose. (e.g. variety of research and educational initiatives at the Foundation for the NIH, Inc). Net assets associated with endowment funds are classified and reported based on the existence or absence or donor-imposed restrictions.
Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote	The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code; accordingly, the accompanying financial statements do not reflect a provision or liability for federal and state income taxes. The Foundation has determined that it does not have any material unrecognized tax benefits or obligations as of December 31, 2023 and 2022.
Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements	Fundraising Direct Expense - -510332
Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990	Fundraising Direct Expense - 510332

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp

Field	Value	IRS element (for citing)
Region	Sub-Saharan Africa	RegionTxt
Offices	0	OfficesCnt
Employee	0	EmployeeCnt
Type Of Activities Conducted	Grantmaking	TypeOfActivitiesConductedTxt
Specific Services Provided	Grantmaking	SpecificServicesProvidedTxt
Region Total Expenditures	$21,970	RegionTotalExpendituresAmt

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	0	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	0	TotalEmployeeCnt
Subtotal Spent	$21,970	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$21,970	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp

Field	Value	IRS element (for citing)
Region	Sub-Saharan Africa	RegionTxt
Purpose Of Grant	Research	PurposeOfGrantTxt
Cash Grant	$21,970	CashGrantAmt
Manner Of Cash Disbursement	Wire Transfer	MannerOfCashDisbursementTxt

Field	Value	IRS element (for citing)
Total501c3 Org	0	Total501c3OrgCnt
Total Other Org	1	TotalOtherOrgCnt
Transfer To Foreign Corp	false	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	false	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds	Program and grants management staff invest considerable effort in providing scientific, administrative, and fiscal oversight for FNIH grants. Scientific and technical progress is monitored through semi-annual and annual reports from the grantees as well as through direct contact with investigators both by teleconference and site visits, and follow up to progress reports and site visits where scientific questions or administrative issues are identified. Scientific report submissions cover a wide range of items including individual objectives and overall progress review, milestone achievement, project plan update, and any other significant changes. Financial reporting is required annually for all of the grantees, and semi-annually for institutions that require additional oversight, such as some developing country institutions. Due diligence procedures, such as FNIH compliance with the USA Patriot Act and IRS requirements on expenditure responsibilities, have been incorporated into the reporting process to ensure that the grantees are complying with grant, legal, financial, and regulatory requirements.
Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements	SUB-SAHARAN AFRICA-Cash
Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements	SUB-SAHARAN AFRICA-Cash

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Solicitation Of Govt Grants	Yes (X)	SolicitationOfGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp

Organization Business Name OrganizationBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	MBP Consulting LLC	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	20 Unity Court	AddressLine1Txt
City	Boston	CityNm
State Abbreviation	MA	StateAbbreviationCd
ZIP	02113	ZIPCd

Field	Value	IRS element (for citing)
Activity	Fundraising Consultancy	ActivityTxt
Fundraiser Control Of Funds	false	FundraiserControlOfFundsInd
Gross Receipts	$0	GrossReceiptsAmt
Retained By Contractor	$94,313	RetainedByContractorAmt
Net To Organization	-$94,313	NetToOrganizationAmt

Field	Value	IRS element (for citing)
Total Gross Receipts	$0	TotalGrossReceiptsAmt
Total Retained By Contractors	$94,313	TotalRetainedByContractorsAmt
Total Net To Organization	-$94,313	TotalNetToOrganizationAmt
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	AL	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	2023 FNIH Award Ceremony	Event1Nm
Gross Receipts Event1	$905,460	GrossReceiptsEvent1Amt
Charitable Contri Event1	$333,929	CharitableContriEvent1Amt
Gross Revenue Event1	$571,531	GrossRevenueEvent1Amt
Food And Beverage Event1	$78,860	FoodAndBeverageEvent1Amt
Other Direct Expenses Event1	$422,773	OtherDirectExpensesEvent1Amt
Event2	2024 FNIH Award Ceremony	Event2Nm
Gross Revenue Event2	$0	GrossRevenueEvent2Amt
Other Direct Expenses Event2	$8,699	OtherDirectExpensesEvent2Amt
Gross Revenue Other Events	$0	GrossRevenueOtherEventsAmt
Gross Receipts Total	$905,460	GrossReceiptsTotalAmt
Charitable Contributions Tot	$333,929	CharitableContributionsTotAmt
Gross Revenue Total Events	$571,531	GrossRevenueTotalEventsAmt
Food And Beverage Total Events	$78,860	FoodAndBeverageTotalEventsAmt
Oth Direct Expnss Total Events	$431,472	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$510,332	DirectExpenseSummaryEventsAmt
Net Income Summary	$61,199	NetIncomeSummaryAmt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (24 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
NIHCC - Clinical Center
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$25,500	Research
NIH NIA
9001 Rockville Pike	Bethesda	MD	20893	520858116	170(c)(1) Govt Unit	$21,728	Research
NIHNCI
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$1,277,547	Research
NIHNIAID
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$2,370,985	Research
NIHNIAMS
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$7,500,000	Research
NIHNINDS
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$645,712	Research
NIH NHLBI
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$979,704	Research
NIHOD
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$102,930	Research
NIH NIMH
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$3,068,409	Research
NIHNEI
9000 Rockville Pike	Bethesda	MD	20892	520858115	170(c)(1) Govt Unit	$1,200	Research
Research Triangle Institute
PO Box 900002	Raleigh	NC	27675	560686338	501(c)(3)	$614,891	Research
University of Alabama at Birmingham
Dept of Pediatric Admin Lowder Bl	Birmingham	AL	35233	636001138	501(c)(3)	$856,050	Research
GeorgeTown University
125 South 9th Street 2nd Floor Sher	Philadelphia	PA	19107	231352651	501(c)(3)	$44,855	Research
University of North Carolina Chapel Hill
3700 O Street NW	Washington	DC	20057	530196603	501(c)(3)	$165,406	Research
The Trustees of Columbia University
104 Airport Drive Suite 2200 Campus	Chapel Hill	NC	27599	800543561	501(c)(3)	$147,571	Research
Trustees of Indiana University
PO Box 29789 General Post Office	New York	NY	10087	135598093	501(c)(3)	$133,249	Research
University of Virginia
The Poplars Building400 E Seventh	Bloomington	IN	47405	356001673	501(c)(3)	$229,524	Research
University of Colorado Denver
PO Box 400195	Charlottesville	VA	22904	546001796	501(c)(3)	$35,939	Research
Duke UnivHuman Vaccine Institute
1100 Fairview Ave N	Seattle	WA	98109	237156071	501(c)(3)	$55,960	Research
Fred Hutchinson Cancer Research Ctr
200 Lothrop St Biomedical Science	Pittsburgh	PA	15213	250965591	501(c)(3)	$683,642	Research
Trustees of Boston University
85 East Newton Streetm M-921	Boston	MA	02118	042103547	501(c)(3)	$663,875	Research
Johns Hopkins University
615 N Wolfe St W1100	Baltimore	MD	21205	150595110	501(c)(3)	$23,454	Research
Friends of Cancer Research
1800 M Street NW Suite 1050 South	Frederick	MD	21702	521983273	501(c)(3)	$138,296	Research
Gordon Research Conferences
5586 Post Road G02	East Greenwich	RI	02818	260150662	501(c)(3)	$60,000	Research

Field	Value	IRS element (for citing)
Total501c3 Org	24	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp

Field	Value	IRS element (for citing)
Grant Type	Awards	GrantTypeTxt
Recipient	5	RecipientCnt
Cash Grant	$402,500	CashGrantAmt
Valuation Method Used	FMV	ValuationMethodUsedDesc

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds.	FormAndLineReferenceDesc
Explanation	Program and grants management staff invest considerable effort in providing scientific, administrative, and fiscal oversight for FNIH grants. Scientific and technical progress is monitored through semi-annual and annual reports from the grantees as well as through direct contact with investigators both by teleconference and site visits, and follow up to progress reports and site visits where scientific questions or administrative issues are identified. Scientific report submissions cover a wide range of items including individual objectives and overall progress review, milestone achievement, project plan update, and any other significant changes. Financial reporting is required annually for all of the grantees, and semi-annually for institutions that require additional oversight, such as for-profit institutions. Due diligence procedures, such as FNIH compliance with the USA Patriot Act and IRS requirements on expenditure responsibilities, have been incorporated into the reporting process to ensure that the grantees are complying with grant, legal, financial, and regulatory requirements. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	false	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Dr Julie L Gerberding
Chief Executive Officer	$513,755	$0	$100,000	$0	$0	$0	$26,400	$0	$16,874	$0	$657,029	$0	$0	$0
David Carmel
Senior Vice President, Chief Growth and Innovation Officer	$397,411	$0	$3,500	$0	$0	$0	$26,400	$0	$13,824	$0	$441,135	$0	$0	$0
David Wholley
Chief Strategy and Business Development (UNTIL NOV.)	$312,942	$0	$25,250	$0	$37,417	$0	$26,400	$0	$13,402	$0	$415,411	$0	$0	$0
Michael Santos
Senior Vice President, Chief Population Health Science Officer	$358,742	$0	$10,000	$0	$0	$0	$26,400	$0	$8,016	$0	$403,158	$0	$0	$0
Joseph Menetski
Senior Vice President, Chief Translational Science Officer	$314,692	$0	$10,000	$0	$0	$0	$26,119	$0	$13,824	$0	$364,635	$0	$0	$0
Donald Hill
Senior Vice President, Chief Financial Officer	$279,166	$0	$10,000	$0	$0	$0	$23,519	$0	$16,874	$0	$329,559	$0	$0	$0
Kevin Klock
Senior Vice President, Chief Operating Officer and General Counsel	$273,492	$0	$10,000	$0	$0	$0	$22,999	$0	$14,824	$0	$321,315	$0	$0	$0
Julie Wolf Rodda
Chief Strategic Alliances and Advancement Officer (UNTIL NOV.)	$126,016	$0	$10,000	$0	$44,927	$0	$11,005	$0	$6,498	$0	$198,446	$0	$0	$0
Stacey Adam
Associate Vice President, Science Partnerships Translational Science	$243,208	$0	$15,000	$0	$0	$0	$20,639	$0	$7,916	$0	$286,763	$0	$0	$0
Steven Hoffmann
Associate Vice President, Science Partnerships Translational Science	$230,048	$0	$10,000	$0	$0	$0	$19,399	$0	$13,824	$0	$273,271	$0	$0	$0
Eva Coyne
Vice President -Controller	$223,374	$0	$7,800	$0	$0	$0	$18,743	$0	$14,053	$0	$263,970	$0	$0	$0
Courtney Silverthorn
Associate Vice President, Science Partnerships Translational Science	$227,930	$0	$8,500	$0	$0	$0	$18,927	$0	$8,276	$0	$263,633	$0	$0	$0
Robert Balthaser
Vice President of Advancement (UNTIL NOV.)	$161,737	$0	$2,500	$0	$56,079	$0	$13,092	$0	$7,203	$0	$240,611	$0	$0	$0

Schedule M IRS990ScheduleM

Drugs And Medical Supplies DrugsAndMedicalSuppliesGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	12	ContributionCnt
Noncash Contributions Rpt F990	$6,019,419	NoncashContributionsRptF990Amt
Method Of Determining Revenues	Market value	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Form8283 Received	0	Form8283ReceivedCnt
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	false	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule M, Part I Explanations of reporting method for number of contributions	FormAndLineReferenceDesc
Explanation	Drugs and medical supplies - The organization is reporting the number of contributions.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (10 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Form 990, Part III, Line 4a Program Service Description	PROGRAM ONE - RESEARCH PROGRAMS - ACCELERATING MEDICINES PARTNERSHIP PROGRAM (AMP) The FNIH manages the Accelerating Medicines Partnership (AMP) program with the interests of the collective scientific and medical research communities in mind. Our mission is to improve understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate new and effective therapies to patients. All AMP projects operate under the broad principle of delivering pre-competitive advancements to the research and medical fields and enabling the broadest possible access and use of AMP research discoveries. A critical component of each public-private partnership in the AMP program is an agreement among partners to make data and analyses arising from the collaboration publicly accessible to benefit the broader biomedical community. Individual AMP projects frequently establish public portals to rapidly disseminate data from their research efforts, and AMP-funded publications are required to be made available publicly within specific timeframes. At the center of the AMP program is a common goal of accelerating new and effective therapies to patients. AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes. Biomarkers Consortium The Biomarkers Consortium convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogates. The Biomarkers Consortium creates and leads cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies. The core operations of the Biomarkers Consortium are supported through contributing membership. Organizations representing private industry (including the pharmaceutical, biotechnology, diagnostics, and information technology industries) and not-for-profit organizations (including associations, advocacy groups, trade organizations, and philanthropic organizations) that wish to support biomarkers development are eligible to become contributing members. GeneConvene The GeneConvene Global Collaborative advances best practices and informed decision making for development of genetic biocontrol technologies to improve public health. GeneConvene offers technical information, advice, training, and coordination for research on gene drive and other genetic biocontrol technologies - technologies that use genetic variants of a target species, like a disease-transmitting mosquito, to control its undesirable impacts. Efforts to control the spread of mosquito-borne diseases save hundreds of thousands of lives every year, but the tools and resources available are not sufficient to protect everyone. Gene drive is recognized as a potentially powerful tool to help control malaria. Genetic biocontrol has been used on disease-transmitting mosquitoes for over 60 years, but scientific advances in the past 20 years have dramatically improved the ability of researchers to engineer new genetic biocontrol approaches, including gene drives. GeneConvene was created to support informed decision making on the open scientific, regulatory, and policy questions raised by these new technologies. In 2023, GeneConvene members published the following: - An article in a special collection volume (organized by GeneConvene Global Collaborative) of Transgenic Research focusing on the regulatory requirements for implementing gene drive technologies in national or regional public health programs. - An article in Frontiers in Bioengineering and Biotechnology considering the approval procedures and market entry strategies for implementing gene drive-modified mosquitoes. - An assessment by a neutral third party, CSIRO, of risks associated with the release of genetically modified mosquitoes by the Target Malaria project. - A multi-country study in Malaria Journal exploring the insights and recommendations of key stakeholders across Africa on the potential of gene drive-modified mosquitoes for malaria control and elimination. Members also: - Supported training activities on operationalization of biosafety oversight and genetically modified organism decision making processes at African institutions. - Advised the United Nations Convention on Biological Diversity on developing guidance for risk assessment of engineered gene drive-modified mosquitoes. RESEARCH PROGRAMS FOR ACCELERATING NEW THERAPIES NIMBLE Results Set Stage for Improved Diagnosis, Treatment of Liver Disease To diagnose metabolic dysfunction-associated steatohepatitis (MASH), a leading cause of liver-related mortality, patients must undergo a liver biopsy, a painful and expensive procedure that carries some risk of death for patients. The Biomarkers Consortium's Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) project aims to identify noninvasive blood-based and imaging biomarkers to assess their performance in diagnosing MASH, compared to liver biopsy, and to evaluate their suitability for monitoring treatment response in clinical trials. By expanding diagnostic options, more healthcare professionals and facilities would be able to diagnose MASH with greater safety, and the use of noninvasive tests may assist enrollment in future studies. - Four noninvasive blood tests for MASH and advanced liver disease were identified for assessment in NIMBLE 2. Study results published inNature Medicine. - Six imaging biomarkers shown to have the potential to measure liver fat, fibrosis, and body composition in those at risk for MASH. Study results published in Radiology. Expanding Access to Gene Therapy for Sickle Cell Disease Worldwide The FDA recently approved two treatments that use gene-editing technologies to mitigate the inherited gene mutation that causes sickle cell disease (SCD). These therapies involve procuring a patient's own bone marrow cells to repair the defective gene outside the body (ex vivo) and then transplanting the modified cells back into the patient's blood. The FNIH has supported, and continues to support, the underlying gene-editing research at NIH's National Heart, Lung, and Blood Institute (NHLBI) that helped lay the foundation for this breakthrough. Still, access to these therapies remains limited for people in low- and middle-income countries that may not have a cell-processing center and related resources necessary for ex vivo gene therapy. This is where the FNIH is seeking to broaden access to critical gene editing therapies for patients with SCD. In partnership with the NHLBI, the FNIH launched a project to explore techniques for administering gene therapy strategies entirely inside a patient's body (in vivo), which would eliminate the need for an advanced healthcare infrastructure and make SCD treatment more broadly available. BGTC Launches Clinical Trial Portfolio There are more than 10,000 known rare genetic diseases, affecting more than 30 million Americans and their families, but there is typically little to no commercial interest in developing treatments for a disorder that may impact only a dozen or so patients, leaving many such patients with little or no hope for beneficial treatments. Gene therapies hold promise for treating such patients, but progress is slowed by uncertainties about manufacturing and a clear regulatory path. Part of the AMP program, the Bespoke Gene Therapy Consortium (BGTC) partnership, now in its second year, brings experts across the biosciences ecosystem together to define the best ways to safely advance these treatments and encourage increased investments in their development. BGTC announced in 2023 the eight rare diseases that will comprise the program's initial clinical trial portfolio, which will pioneer a novel approach to the development of adeno-associated virus (AAV) gene therapy for rare diseases. The goal is to demonstrate that manufacturing and testing standards can provide a streamlined approval pathway for first-in-human clinical trials.
Form 990, Part VI, Line 1a Delegate broad authority to a committee	THE BOARD HAS AN EXECUTIVE COMMITTEE, WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS.
Form 990, Part VI, Line 4 Significant changes to organizational documents	The FNIH By-Laws were amended in October 2023 to create a category of Board membership for Founding Directors.
Form 990, Part VI, Line 11b Review of form 990 by governing body	Prior to the submission of the Foundation for NIH's Form 990 to the Internal Revenue Service, each voting member of the board of directors shall be provided with a copy of the draft Form 990 as approved by the Chief Financial Officer.
Form 990, Part VI, Line 12c Conflict of interest policy	DIRECTORS, OFFICERS AND EMPLOYEES ARE REQUIRED TO ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT THEY HAVE: O RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY O READ, UNDERSTOOD AND AGREED TO COMPLY WITH THE POLICY O RECEIVED AND REVIEWED A LISTING OF CORPORATE AND FOUNDATION DONORS, CONTRACTORS, VENDORS, GRANTEES, PRINCIPAL INVESTIGATORS AND FINANCIAL INSTITUTIONS WITH WHOM THE FNIH HAS A CURRENT RELATIONSHIP O NO ACTUAL OR APPARENT CONFLICTS OF INTEREST OTHER THAN THOSE DISCLOSED IN THE STATEMENT. THEY MUST ALSO MAKE CERTAIN NOTIFICATIONS IN PARTICULAR CIRCUMSTANCES. THE CONFLICT OF INTEREST POLICY ALSO HAS MECHANISMS FOR HANDLING SUCH CONFLICTS.
Form 990, Part VI, Line 15a Process to establish compensation of top management official	The Compensation Committee of the Board reviewed and concurred with the CEO's decisions establishing and adjusting the senior executive team's annual salaries and related compensation decisions. The Compensation Committee also approved the compensation level of the CEO and related compensation decisions.
Form 990, Part VI, Line 15b Process to establish compensation of other employees	The Compensation Committee of the Board reviewed and concurred with the CEO's decisions establishing and adjusting the senior executive team's annual salaries and related compensation decisions. The Compensation Committee also approved the compensation level of the CEO and related compensation decisions.
Form 990, Part VI, Line 19 Required documents available to the public	All such documents are available upon request. In addition, the governing documents and financial statements are available on the FNIH website.
Form 990, Part X, Column (B) Cash & Investments	Approximately $122 Million of FNIH's Cash and Investments are invested in high quality short-term fixed income securities which are committed to FNIH's restricted assets.
Form 990, Part XII, Line 2c Change of oversight process or selection process	PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.